Wladimir Hogenhuis
Director/Board Member chez REZOLUTE, INC.
Fortune : 83 367 $ au 31/03/2024
Profil
Wladimir Hogenhuis is currently the President, Chief Executive Officer & Director at Driver Bioengineering, Inc., an Independent Director at Rezolute, Inc., a Director at GATT Technologies BV, and a Director at IHP Therapeutics, Inc. He was previously a Director at Vision 2020, the General Manager-Neuroscience at Merck & Co., Inc., the Chief Operating Officer at Ultragenyx Pharmaceutical, Inc., and the Senior Vice President at GSK Plc.
Hogenhuis holds a doctorate from the University of Leiden and an MBA from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
REZOLUTE, INC.
0,08% | 23/01/2024 | 32 693 ( 0,08% ) | 83 367 $ | 31/03/2024 |
Postes actifs de Wladimir Hogenhuis
| Sociétés | Poste | Début |
|---|---|---|
| REZOLUTE, INC. | Director/Board Member | 02/03/2021 |
GATT Technologies BV
 GATT Technologies BV Medical SpecialtiesHealth Technology GATT Technologies BV develops a soluble surgical tape. It manufactures a polymer-based general adhesive tissue tape that is used as a surgical sealant for various surgical applications. The company was founded in August 2011 by Johan Bender and André de Lege and is headquartered in Nijmegen, the Netherlands. | Director/Board Member | 01/05/2020 |
| IHP Therapeutics, Inc. | Director/Board Member | - |
Driver Bioengineering, Inc.
 Driver Bioengineering, Inc. Medical SpecialtiesHealth Technology Driver Bioengineering, Inc. develops modular, drug-responsive, titratable, ribozyme based control devices for chimeric antigen receptor. It engages in building control systems for chimeric antigen receptor (CAR) T-cell therapeutics. The company was founded by Gusti Zeiner, Christina Smolke and Benjamin Wang on May 12, 2015 and is headquartered in Menlo Park, CA. | Chief Executive Officer | 28/04/2022 |
Anciens postes connus de Wladimir Hogenhuis
| Sociétés | Poste | Fin |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Chief Operating Officer | 10/01/2020 |
| GSK PLC | Corporate Officer/Principal | 01/09/2018 |
| Vision 2020 | Director/Board Member | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Formation de Wladimir Hogenhuis
| University of Leiden | Doctorate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| GSK PLC | Health Technology |
| REZOLUTE, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
| Vision 2020 | |
GATT Technologies BV
GATT Technologies BV Medical SpecialtiesHealth Technology GATT Technologies BV develops a soluble surgical tape. It manufactures a polymer-based general adhesive tissue tape that is used as a surgical sealant for various surgical applications. The company was founded in August 2011 by Johan Bender and André de Lege and is headquartered in Nijmegen, the Netherlands. | Health Technology |
Driver Bioengineering, Inc.
Driver Bioengineering, Inc. Medical SpecialtiesHealth Technology Driver Bioengineering, Inc. develops modular, drug-responsive, titratable, ribozyme based control devices for chimeric antigen receptor. It engages in building control systems for chimeric antigen receptor (CAR) T-cell therapeutics. The company was founded by Gusti Zeiner, Christina Smolke and Benjamin Wang on May 12, 2015 and is headquartered in Menlo Park, CA. | Health Technology |
| IHP Therapeutics, Inc. |
